Michael A. Kozminski

Baseline characteristics predict risk of progression and response to combined medical therapy for benign prostatic hyperplasia ( <scp>BPH</scp> )

Michael A. Kozminski, John T. Wei, Jason Nelson et al. · British Journal of Urology · 2014 · 47 citations · Full text

Medicine, Biostatistics, Urology +14

Intravesical instillation of gentamicin sulfate: In vitro, rat, canine, and human studies

Julian Wan, Michael A. Kozminski, Stewart C. Wang et al. · Urology · 1994 · 45 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +7

How Long and How Well

Michael A. Kozminski, Peter J. Neumann, Eric Nadler et al. · Medical Decision Making · 2010 · 26 citations

Pharmacy, Oncology, Pharmacoeconomics +15

In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival

Peter A. Ubel, Scott R. Berry, Eric Nadler et al. · Health Affairs · 2012 · 26 citations

Pharmacy, Oncology, Pharmacoeconomics +16

Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy

Michael A. Kozminski, Scott A. Tomlins, Adam Cole et al. · Urologic Oncology Seminars and Original Investigations · 2016 · 26 citations

Medicine, Surgery, Urology +14